Cytogenetic and Genome Research
Eukaryotic translation termination factor gene (ETF1/eRF1) maps at D5S500 in a commonly deleted region of chromosome 5q31 in malignant myeloid diseasesGuenet L.a · Henry C.b · Toutain B.c · Dubourg C.a · Le Gall J.Y.a · David V.a · Le Treut A.caDépartement de Biochimie et Biologie Moléculaire et UPR41 CNRS, Faculté de Médecine, Rennes; bService de Cytogénétique et Biologie Cellulaire, CHRU Pontchaillou, Rennes; cDépartement de Biochimie et Biologie Moléculaire, Laboratoire de Biochimie Médicale A, Faculté de Médecine, Rennes (France)
|
|
Cytogenet Cell Genet 88:82–86 (2000)
Log in to MyKarger to check if you already have access to this content.
KAB
Buy a Karger Article Bundle (KAB) and profit from a discount!
If you would like to redeem your KAB credit, please log in.
Save over 20% compared to the individual article price.
* The final prices may differ from the prices shown due to specifics of VAT rules.
Article / Publication Details
First-Page Preview
Published online: March 27, 2000
Issue release date: 2000
Number of Print Pages: 5
Number of Figures: 3
Number of Tables: 0
ISSN: 1424-8581 (Print)
eISSN: 1424-859X (Online)
For additional information: https://www.karger.com/CGR
Abstract
The human genome contains four ETF1 (eukaryotic translation termination factor 1) homologous sequences, localized on chromosomes 5, 6, 7 and X, and corresponding to a functional gene on chromosome 5 and three processed pseudogenes on the other chromosomes. ETF1 genomic or cDNA probes were mapped by fluorescence in situ hybridization to 5q31, 6p21, 7q11 and Xp11.4→p11.1. A microsatellite marker (D5S500) was identified in intron 7 of the functional ETF1 gene providing its exact position in the 5q31 band. Thus, the ETF1 gene is located in a 5q region which contains unidentified genes responsible for genetic or malignant disorders, and it might be considered as a candidate gene involved in the pathogenesis of these diseases.
© 2000 S. Karger AG, Basel
Related Articles:
References
- Altschul SF, Madden TL, Schäffer AA, Zhang J, Zhang Z, Miller W, Lipman DJ: Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. Nucl Acids Res 25:3389–3402 (1997).
- Amiel A, Fridman K, Elis A, Gaber E, Manor Y, Fejgin M, Lishner M: Deletion 5q31 in patients with stable, melphalan-treated multiple myeloma. Cancer Genet Cytogenet 113:45–48 (1999).
- Bartoloni L, Horrigan SK, Viles KD, Gilchrist JM, Stajich JM, Vance JM, Yamaoka LH, Pericak-Vance MA, Westbrook CA, Speer MC: Use of a CEPH meiotic breakpoint panel to refine the locus of limb-girdle muscular dystrophy type 1A (LGMD1A) to a 2-Mb interval on 5q31. Genomics 54:250–255 (1998).
- Chauvel B, Dorval I, Fergelot P, Pichon L, Giffon T, Gicquel I, Le Gall JY, David V: A human homologue to the yeast omnipotent suppressor 45 maps 100 kb centromeric to HLA-A. Immunogenetics 41:380–382 (1995).
- Chumakov IM, Rigault P, Le Gall I, Bellanné-Chantelot C, Billault A, Guillou S, Soularue P, Guasconi G, Poullier E, Gros I, et al: A YAC contig map of the human genome. Nature 377:175–297 (1995).
- Drugeon G, Jean-Jean O, Frolova L, Le Goff X, Philippe M, Kisselev L, Haenni AL: Eukaryotic release factor 1 (eRF1) abolishes readthrough and competes with suppressor tRNAs at all three termination codons in messenger RNA. Nucl Acids Res 25:2254–2258 (1997).
- El Kahloun A, Chauvel B, Mauvieux V, Dorval I, Jouanolle AM, Gicquel I, Le Gall JY, David V: Localization of seven new genes around the HLA-A locus. Hum Mol Genet 2:55–60 (1993).
- Fairman J, Chumakov I, Chinault AC, Nowell PC, Nagarajan L: Physical mapping of the minimal region of loss in 5q-chromosome. Proc natl Acad Sci, USA 92:7406–7410 (1995).
- Feit H, Silbergleit A, Schneider LB, Gutierrez JA, Fitoussi RP, Réyès C, Rouleau GA, Brais B, Jackson CE, Beckmann JS, Seboun E: Vocal cord and pharyngeal weakness with autosomal dominant distal myopathy: clinical description and gene localization to 5q31. Am J hum Genet 63:1732–1742 (1998).
- Frolova L, Le Goff X, Rasmussen HH, Cheperegin S, Drugeon G, Kress M, Arman I, Haenni AL, Celis JE, Philippe M, Justesen J, Kisselev L: A highly conserved eukaryotic protein family possessing properties of polypeptide chain release factor. Nature 372:701–703 (1994).
-
Grenett HE, Bounelis P, Fuller GM: Identification of a human cDNA with high homology to yeast omnipotent suppressor 45. Gene 110:239–243 (1992a).
-
Grenett HE, Eipers PG, Kidd VJ, Bounelis P, Fuller GM: Chromosomal localization of a human cDNA containing a DIDS binding domain and demonstrating high homology to yeast omnipotent suppressor 45. Somat Cell Mol Genet 18:97–102 (1992b).
- Guenet L, Toutain B, Guilleret I, Chauvel B, Deaven LL, Longmire JL, Le Gall JY, David V, Le Treut A: Human release factor eRF1: structural organisation of the unique functional gene on chromosome 5 and of the three processed pseudogenes. FEBS Lett 454:131–136 (1999).
- Horrigan SK, Bartoloni L, Speer MC, Fulton N, Kravarusic J, Ramesar R, Vance JM, Yamaoka LH, Westbrook CA: A radiation hybrid breakpoint map of the acute myeloid leukemia (AML) and limb-girdle muscular dystrophy 1A (LGMD1A) regions of chromosome 5q31 localizing 122 expressed sequences. Genomics 57:24–35 (1999).
- Horrigan SK, Westbrook CA, Kim AH, Banerjee M, Stock W, Larson RA: Polymerase chain reaction-based diagnosis of del (5q) in acute myeloid leukemia and myelodysplastic syndrome identifies a minimal deletion interval. Blood 88:2665–2670 (1996).
- Jaju RJ, Boultwood J, Oliver FJ, Kostrzewa M, Fidler C, Parker N, McPherson JD, Morris SW, Müller U, Wainscoat JS, Kearney L: Molecular cytogenetic delineation of the critical deleted region in the 5q– syndrome. Genes Chrom Cancer 22:251–256 (1998).
- Le Beau MM, Albain KS, Larson RA, Vardiman JW, Davis EM, Blough RR, Golomb HM, Rowley JD: Clinical and cytogenetic correlations in 63 patients with therapy-related myelodysplastic syndromes and acute nonlymphocytic leukemia: further evidence for characteristic abnormalities of chromosomes no. 5 and 7. J Clin Oncol 4:325–345 (1986).
- Le Beau MM, Espinosa R III, Neuman WL, Stock W, Roulston D, Larson RA, Keinanen M, Westbrook CA: Cytogenetic and molecular delineation of the smallest commonly deleted region of chromosome 5 in malignant myeloid diseases. Proc natl Acad Sci, USA 90:5484–5488 (1993).
- Le Goff X, Philippe M, Jean-Jean O: Overexpression of human release factor 1 alone has an antisuppressor effect in human cells. Mol Cell Biol 17:3164–3172 (1997).
- Nagarajan L, Zavadil J, Claxton D, Lu X, Fairman J, Warrington JA, Wasmuth JJ, Chinault AC, Sever CE, Slovak ML, Willman CL, Deisseroth AB: Consistent loss of the D5S89 locus mapping telomeric to the interleukin gene cluster and centromeric to EGR-1 in patients with 5q– chromosome. Blood 83:199–208 (1994).
- Nimer SD, Golde DW: The 5q– abnormality. Blood 70:1705–1712 (1987).
- Rihet P, Traore Y, Abel L, Aucan C, Traore-Leroux T, Fumoux F: Malaria in humans: Plasmodium falciparum blood infection levels are linked to chromosome 5q31→q33. Am J hum Genet 63:498–505 (1998).
- Saltman DL, Dolganov GM, Warrington JA, Wasmuth JJ, Lovett M: A physical map of 15 loci on human chromosome 5q23→q33 by two-color fluorescence in situ hybridization. Genomics 16:726–732 (1993).
- Spring B, Fonatsch C, Muller C, Pawelec G, Kompf J, Wernet P, Ziegler A: Refinement of HLA gene mapping with induced B-cell line mutants. Immunogenetics 21:277–291 (1985).
- Troye Blomberg M, Berzins K, Perlmann P: T-cell control of immunity to the asexual blood stages of the malaria parasite. Crit Rev Immunol 14:131–155 (1994).
- Urbero B, Eurwilaichitr L, Stanfield I, Tassan JP, Le Goff X, Kress M, Tuite MF: Expression of the release factor eRF1 (Sup45p) gene of higher eukaryotes in yeast and mammalian tissues. Biochimie 79:27–36 (1997).
- Viegas-Péquignot E, Dutrillaux B, Magdelenat H, Copey-Moisan M: Mapping of single-copy DNA sequences on human chromosomes by in situ hybridization with biotinylated probes: enhancement of detection sensitivity by intensified-fluorescence digital-imaging microscopy. Proc natl Acad Sci USA 86:582–586 (1989).
- Warrington JA, Hall LV, Hinton LM, Miller JN, Wasmuth JJ, Lovett M: Radiation hybrid map of 13 loci on the long arm of chromosome 5. Genomics 11:701–708 (1991).
- Warrington JA, Bailey SK, Armstrong E, Aprelikova O, Alitalo K, Dolganov GM, Wilcox AS, Sikela JM, Wolfe SF, Lovett M, Wasmuth JJ: A radiation hybrid map of 18 growth factor, growth factor receptor, hormone receptor, or neurotransmitter receptor genes on the distal region of the long arm of chromosome 5. Genomics 13:803–808 (1992).
- Zhao N, Stoffel A, Wang PW, Eisenbart JD, Espinosa R, Larson RA, Le Beau MM: Molecular delineation of the smallest commonly deleted region of chromosome 5 in malignant myeloid diseases to 1–1.5 Mb and preparation of a PAC-based physical map. Proc natl Acad Sci, USA 94:6948–6953 (1997).
- Zhouravleva G, Frolova L, Le Goff X, Le Guellec R, Inge-Vechtomov S, Kisselev L, Philippe M: Termination of translation in eukaryotes is governed by two interacting polypeptide chain release factors, eRF1 and eRF3. EMBO J 14:4065–4072 (1995).
Article / Publication Details
First-Page Preview
Published online: March 27, 2000
Issue release date: 2000
Number of Print Pages: 5
Number of Figures: 3
Number of Tables: 0
ISSN: 1424-8581 (Print)
eISSN: 1424-859X (Online)
For additional information: https://www.karger.com/CGR
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
Get Permission
PubMed ID
